Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in P

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in P
(NASDAQ: GMAB) Delayed: 34.69 -0.05 (0.14%)
Previous Close $34.74    52 Week High $ 
Open $34.70    52 Week Low $ 
Day High $34.87    P/E N/A 
Day Low $34.36    EPS $ 
Volume 1,577,456